[go: up one dir, main page]
Jump to content

Monica Bertagnolli

From Wikipedia, the free encyclopedia

Monica Bertagnolli
Portrait photograph of Dr. Monica Bertagnolli
Bertagnolli in 2022
17th Director of the National Institutes of Health
Incumbent
Assumed office
November 9, 2023
PresidentJoe Biden
Preceded byLawrence A. Tabak (acting)
Francis Collins
16th Director of the National Cancer Institute
In office
October 3, 2022 – November 9, 2023
PresidentJoe Biden
DeputyDouglas R. Lowy
Preceded byNorman Sharpless
Succeeded byKimryn Rathmell
Personal details
Born1959 (age 64–65)
EducationPrinceton University (BS)
University of Utah (MD)
Scientific career
FieldsSurgical oncology
Gastrointestinal cancer
Adenomatous polyposis coli
Colorectal cancer
InstitutionsDana–Farber Cancer Institute
Harvard Medical School
NewYork-Presbyterian Hospital

Monica Bertagnolli (born 1959) is an American surgical oncologist and the 17th director of the National Institutes of Health. She previously served as the 16th director of the National Cancer Institute (NCI).[1] Prior to her governmental positions, she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School.[2]

She has advocated for inclusion of rural communities in clinical studies and served as Chair of the Alliance for Clinical Trials in Oncology until her appointment to lead the NCI.[3] Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and soft tissue sarcomas.[4] She is the former President of the American Society of Clinical Oncology and was inducted into the National Academy of Medicine in 2021.[5][6]

Early life and education

[edit]

Bertagnolli grew up on a cattle ranch in Wyoming.[7] Her parents were first generation French Basque and Italian immigrants.[8][9] She earned a BSE in biochemical engineering from Princeton University.[10][11] She studied medicine at the University of Utah School of Medicine and did her surgical residency at Brigham and Women's Hospital. She became board certified in 1993.[12]

Cancer research

[edit]

In 1994, Bertagnolli began as an associate surgeon at the Strang Cancer Prevention Center and attending surgeon at NewYork-Presbyterian Hospital–Cornell.[10] She joined the faculty at Harvard Medical School in 1999 and was appointed at Dana–Farber Cancer Institute in 2000.[10] Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and is an expert in treating soft-tissue sarcoma.[8] She became the Chief of Surgical Oncology at the Dana–Farber Cancer Institute in 2007, and was the first woman to hold such a position.[8] Bertagnolli's laboratory at the Dana-Farber / Harvard Cancer Center studies the role of Adenomatous polyposis coli (APC) mutations in colorectal carcinogenesis through animal studies and human clinical trials.[13]

Selected publications

[edit]

Her publications include:

  • Molecular origins of cancer: Molecular basis of colorectal cancer[14]
  • Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention[15]
  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq[16]

NIH director

[edit]

In May 2023, President Biden nominated Bertagnolli to serve as the director of the National Institutes of Health.[17] Dr. Bertagnolli was confirmed by the United States Senate on November 7, 2023. She is the second woman director of the NIH.[18]

Awards and honors

[edit]

Bertagnolli's awards and honors include:

Personal life

[edit]

Bertagnolli is married and has two sons.[8] After a routine mammogram, Bertagnolli received an early-stage breast cancer diagnosis in November 2022.[24]

References

[edit]
  1. ^ "Monica Bertagnolli becomes NCI director - NCI". www.cancer.gov. October 3, 2022. Retrieved October 21, 2022.
  2. ^ Monica Bertagnolli publications from Europe PubMed Central
  3. ^ Dutchen, Stephanie. "In the Picture". Harvard Medicine magazine. Retrieved October 24, 2021.
  4. ^ www.dana-farber.org/find-a-doctor/monica-m-bertagnolli/ Edit this at Wikidata
  5. ^ a b "ASCO elects Dana-Farber/Brigham and Women's Monica Bertagnolli, MD, as 2018-19 president - Dana-Farber Cancer Institute | Boston, MA". dana-farber.org. Retrieved October 24, 2021.
  6. ^ a b "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. October 18, 2021. Retrieved October 24, 2021.
  7. ^ "Women's History Month - Monica Bertagnnolli, MD". AAUW California. March 3, 2018. Retrieved October 24, 2021.
  8. ^ a b c d "Hub's Humble Cancer Hero; Surgical 'Superstar' Dr. Monica Bertagnolli Tackles the Tough Cases". redorbit.com. June 24, 2007. Retrieved October 24, 2021.
  9. ^ "NCI Director Dr. Monica M. Bertagnolli - NCI". www.cancer.gov. October 3, 2022. Retrieved November 23, 2022.
  10. ^ a b c d "Monica M. Bertagnolli, MD, FACS, FASCO". ASCO. Retrieved October 24, 2021.
  11. ^ Piana, Ronald (June 3, 2018). "Monica M. Bertagnolli, MD, FASCO, a Cattle Rancher's Daughter, Becomes ASCO President". Retrieved October 24, 2021.
  12. ^ "Monica M. Bertagnolli, MD - Dana–Farber Cancer Institute | Boston, MA". dana-farber.org. Archived from the original on October 24, 2021. Retrieved October 24, 2021.
  13. ^ "Monica M. Bertagnolli, MD". Dana-Farber / Harvard Cancer Center. Retrieved October 24, 2021.
  14. ^ Sanford D Markowitz; Monica M Bertagnolli (December 17, 2009). "Molecular origins of cancer: Molecular basis of colorectal cancer". The New England Journal of Medicine. 361 (25): 2449–60. doi:10.1056/NEJMRA0804588. ISSN 0028-4793. PMC 2843693. PMID 20018966. Wikidata Q24617331.
  15. ^ Solomon SD; McMurray JJ; Pfeffer MA; et al. (March 17, 2005). "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention". The New England Journal of Medicine. 352 (11): 1071–80. doi:10.1056/NEJMOA050405. ISSN 0028-4793. PMID 15713944. Wikidata Q29620087.
  16. ^ Itay Tirosh; Benjamin Izar; Sanjay M Prakadan; et al. (April 1, 2016). "Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq". Science. 352 (6282): 189–196. doi:10.1126/SCIENCE.AAD0501. ISSN 0036-8075. PMC 4944528. PMID 27124452. Wikidata Q37094024.
  17. ^ Kekatos, Mary (May 15, 2023). "Biden plans to nominate Dr. Monica Bertagnolli at NIH". ABC News. Retrieved May 15, 2023.
  18. ^ Stolberg, Sheryl Gay (November 7, 2023). "Senate Confirms Biden's Pick for N.I.H. Director Over Sanders's Objections". The New York Times. ISSN 0362-4331. Retrieved November 9, 2023.
  19. ^ "2015 Recipients of "The Charlie" – Pfizer and The Alliance for Clinical Trials in Oncology | CEO Roundtable on Cancer". ceoroundtableoncancer.org. Retrieved October 24, 2021.
  20. ^ "Two Dana-Farber faculty elected to National Academy of Medicine - Dana–Farber Cancer Institute | Boston, MA". dana-farber.org. Retrieved October 24, 2021.
  21. ^ "Monica Bertagnolli Bio". cancer.org. Retrieved October 24, 2021.
  22. ^ "100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023". OncoDaily. September 16, 2023.
  23. ^ "Golden Plate Awardees of the American Academy of Achievement". achievement.org. American Academy of Achievement.
  24. ^ McGinley, Laurie (December 14, 2022). "For new NCI director, work turns personal: She is diagnosed with cancer". The Washington Post. Retrieved December 14, 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Monica_Bertagnolli&oldid=1249227420"